In conclusion, we developed and empirically verified a new and simple ex vivo-expansion protocol using IL-2, IL-12, IL-18, CD16, CD56 and NKp46 for preparing high ratio of NK cells in effector cells (MYJ1633) and demonstrated their cytotoxicity against liver cancer in vitro and in vivo. Here, NCAM1 is linked to liver cancer.